Blarcamesine hydrochloride is under clinical development by Anavex Life Sciences and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Blarcamesine hydrochloride’s likelihood of approval (LoA) and phase transition for Angelman Syndrome took place on 18 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Blarcamesine hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Blarcamesine hydrochloride overview
Blarcamesine hydrochloride (ANAVEX-273, AE-37) is under development for the treatment of Angelman syndrome, fragile X syndrome, infantile spasms, Alzheimer’s disease, gait abnormality, Parkinson's disease dementia, tuberous sclerosis, Rett syndrome and undisclosed rare disease. The drug candidate is administered orally or intravenously. The drug candidate is a tetrahydrofuran disease modification agent. It is a prodrug of ANAVEX 19-144. Anavex-273 targets sigma-1, muscarinic M1-4 receptors, sodium channel site 2 and NMDA receptor. The drug candidate is based on SIGMACEPTOR-N program. It was also under development for stroke, amyotrophic lateral sclerosis, anxiety, amnesia, depression and multiple sclerosis.
Anavex Life Sciences overview
Anavex Life Sciences (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and other central nervous systems (CNS) diseases, pain, and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer infantile spasms, fragile X syndrome, Angelman syndrome, multiple sclerosis, depression, stroke, frontotemporal dementia, visceral pain, acute and neuropathic Pain, and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex’s lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.
Quick View Blarcamesine hydrochloride LOA Data
|Highest Development Stage|